Search clinical trials for: Atazanavir Sulphate Ritonavir Rosiglitazone maleate

Total 240 results

Bristol-Myers Squibb

Completed

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

HIV Infections

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Rosiglitazone in Treating Patients With Liposarcoma

Sarcoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Terminated

Rosiglitazone in Treating Patients With Pituitary Tumors

Brain and Central Nervous System Tumors

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Head and Neck Cancer

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Terminated

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Cushing's Disease

United States
University of British Columbia

Completed

Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels

HIV Infections | Atherosclerosis

Canada
Asan Medical Center
Bristol-Myers Squibb

Unknown

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

Atazanavir

Korea, Republic of
Bristol-Myers Squibb

Completed

Drug Interaction Study With Proton Pump Inhibitor

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

HIV Infections | Hyperinsulinemia | Lipodystrophy

United States
GlaxoSmithKline

Completed

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

Diabetes Mellitus, Type 2

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Bristol-Myers Squibb

Completed

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

HIV Infections | Protease Inhibitor

United States
University of Liverpool
University of Cape Town; Desmond Tutu HIV Foundation; Infectious Diseases Institute... and other collaborators

Completed

Pharmacokinetics of Atazanavir in Special Populations (VirTUAL WP5)

HIV/AIDS | Tuberculosis

Uganda, South Africa
Bristol-Myers Squibb

Completed

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (PRINCE1)

HIV Infections

Thailand, Chile, Peru, Brazil, Mexico, South Africa
GlaxoSmithKline

Completed

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Diabetes Mellitus, Type 2

United States, Canada, Korea, Republic of, Australia, New Zealand, Mexico, Brazil
National Cancer Institute (NCI)

Completed

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Oral Leukoplakia

United States
GlaxoSmithKline

Completed

Avandamet Bioequivalence Study Brazil - Fed Administration

Diabetes Mellitus, Type 2

Brazil
University of British Columbia

Completed

Switch to Unboosted Atazanavir With Tenofovir Study (SUAT)

HIV Infection

Canada
Fundacion SEIMC-GESIDA
Bristol-Myers Squibb

Completed

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy (SALT)

HIV Infection

Spain
GlaxoSmithKline

Completed

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Atherosclerosis

United States, Russian Federation, Spain, Germany, Korea, Republic of, Sweden, Canada, Netherlands, Thailand, Hong Kong, Argentina, France, Mexico, Greece, Poland, Italy, India, Brazil, Latvia, Czech Republic
University of California, San Francisco

Completed

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Healthy

United States
Bristol-Myers Squibb

Completed

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) (INDUMA)

HIV Infections

Spain, Italy, United Kingdom, France, Russian Federation, Ireland, Germany, Latvia, Estonia, Portugal
Bristol-Myers Squibb

Completed

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

HIV Infections

United States, United Kingdom
Catholic University of the Sacred Heart

Completed

Atazanavir/r + Lamivudine Dual Therapy (ATLAS)

Human Immunodeficiency Virus

Italy
Bristol-Myers Squibb

Completed

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

HIV

Argentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
Canadian Heart Research Centre
GlaxoSmithKline

Completed

Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) (AVALANCHE)

Type 2 Diabetes Mellitus

Canada
International Antiviral Therapy Evaluation Center
Gilead Sciences; Hoffmann-La Roche

Completed

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

HIV Infections

Netherlands
Bristol-Myers Squibb

Completed

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

HIV Infections

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (PRINCE2)

HIV

United States, Chile, Spain, South Africa, Mexico, Argentina, Poland, Brazil, Russian Federation, Romania, United Kingdom
Bristol-Myers Squibb

Completed

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

HIV Infections

United States
Bristol-Myers Squibb

Completed

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

HIV Infections

United States
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

HIV Infections

Japan
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland
Bristol-Myers Squibb

Completed

ATV/Ritonavir Nevirapine Interaction (USPAC)

HIV Infections

United Kingdom, United States
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Metabolic Effects of Switching Kaletra to Boosted Reyataz

HIV Infections

United States
St Stephens Aids Trust

Completed

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

HIV Infections | HIV

United Kingdom
The University of Texas Health Science Center,...

Completed

"The Once A Day Protease Inhibitor Regimens"

HIV Infections

United States
Obafemi Awolowo University
University of Liverpool

Completed

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Drug Interaction

Nigeria
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Endothelial Dysfunction

United States
Catholic University of the Sacred Heart

Completed

Atazanavir and Lamivudine for Treatment Simplification (AtLaS)

HIV Infections

Italy
Bristol-Myers Squibb

Completed

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (OREY)

Human Immunodeficiency Virus (HIV) Infections

Spain
Clinical Alliance for Research & Education - Infectious...
GlaxoSmithKline

Unknown

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

HIV Infections | Lipodystrophy

United States
Bristol-Myers Squibb

Completed

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

HIV Infections

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
IRCCS San Raffaele
Bristol-Myers Squibb

Completed

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

HIV-1 Infection

Italy
Bristol-Myers Squibb

Completed

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

HIV Infections

United States, Canada, Argentina, Belgium, Chile, Mexico, Spain, Italy, Australia, Brazil, France, Puerto Rico, United Kingdom, Netherlands, Peru
Bristol-Myers Squibb

Completed

Atazanavir Twice Daily

HIV Infections | Protease Inhibitor

United States
Centre de Recherches et d'Etude sur la Pathologie...
INSERM UMR S 1136

Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients (ATALOW)

HIV-1 Infection

France
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

HIV Infections | Lipodystrophy | Wasting Disease

United States

Search clinical trials for: Atazanavir Sulphate Ritonavir Rosiglitazone maleate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations